Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Ms. Karen L. Hale

Chief Legal Officer

Dr. Vasant  Narasimhan M.D.

Chief Executive Officer

Mr. Victor  Bulto

President of US

Dr. Klaus  Moosmayer Ph.D.

Chief Ethics, Risk & Compliance Officer

Ms. Sloan  Simpson

Global Head of Investor Relations

Dr. Robert  Kowalski Pharm.D.

Chief People & Organization Officer

Paul  Penepent

Head of Group Financial Reporting and Accounting

Dr. Patrick  Horber M.D.

President of International

Mr. Harry  Kirsch

Chief Financial Officer

Dr. Steffen  Lang Ph.D.

President of Operations

Novartis AG

Novartis AG Ledningsstruktur

Information om ledningen